When applied to large areas of the skin for a long time, especially when using occlusive dressings may develop systemic corticosteroids. In view of this, patients should be observed for signs of suppressing function of the hypothalamic-pituitary-adrenal system and the development of Cushing's syndrome.
Uniderm® cream should be avoided in the eyes.
Propylene glycol, which is part of the preparation, may cause irritation at the site of application. In such cases, discontinue the use of Uniderm® cream and prescribe appropriate treatment.
It should be borne in mind that the GCS is able to change the manifestations of certain skin diseases, which can make it difficult to diagnose. In addition, the use of GCS may be the cause of delayed wound healing.
With prolonged therapy with SCS, sudden discontinuation of therapy can lead to the development of a rebound syndrome, manifested in the form of dermatitis with intense reddening of the skin and a burning sensation. Therefore, after a long course of treatment, the drug should be canceled gradually, for example, by switching to an intermittent treatment regimen before it is completely discontinued.
Pediatric Use
The safety and efficacy of Uniderm® cream in topical application in children for more than 6 weeks have not been studied.
Due to the fact that the ratio of surface area and body weight is greater in children than in adults, children are at greater risk of suppressing the function of the hypothalamic-pituitary-adrenal system and the development of Cushing's syndrome with any local GCS.
Long-term treatment of children with SCS can lead to disruption of their growth and development.
Children should receive a minimum dose of the drug sufficient to achieve the effect. In children from 6 months to 2 years old, the course of treatment should not exceed 5 days.